Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival
Author
Maybury, Bernard DJames, Lisa J
Phillips, Neil
Venkatadasari, Indrani
Qureshi, Iman
Riley, James
Talbot, Georgina
Moosai, Shivir
Giles, Hannah
Chadderton, Nicola
Dowds, James
Rakesh, Pallav
Crosland, Henry
Haslam, Aidan
Lane, Sarah
Vega Gonzalez, Monica
Davies, David
Cherian, George
Shenouda, Amir
Kaudlay, Praveen
Starczynski, Jane
Rudzki, Zbigniew
Chaganti, Sridhar
Affiliation
University Hospitals Birmingham NHS Foundation Trust; University Hospitals of the North Midlands NHS Trust; The Royal Wolverhampton NHS Trust; University Hospitals Coventry and Warwickshire NHS Foundation Trust; The Dudley Group NHS Foundation Trust; Shrewsbury and Telford Hospital NHS Trust; Walsall Healthcare NHS Trust; Sandwell and West Birmingham Hospitals NHS TrustPublication date
2024-07-04Subject
Oncology
Metadata
Show full item recordAbstract
A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.Citation
Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival. Blood. 2024 Apr 22:blood.2024024048.Type
ArticlePMID
38648564Journal
BloodPublisher
American Society of Hematologyae974a485f413a2113503eed53cd6c53
10.1182/blood.2024024048